A Phase I-II Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs H3B-6545 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- Sponsors H3 Biomedicine
- 31 Aug 2018 Biomarkers information updated
- 26 Jul 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
- 26 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.